FDA Sunscreen Rules in 2026 After 40: Final Orders vs SPF 60+ Proposal

Bottom line, checked October 30, 2026: A sunscreen article should not treat an FDA proposed rule as if it were in force. The FDA issued a June 10, 2026 final order adding bemotrizinol and a PABA/trolamine salicylate final-order action dated September 10, 2026 on the FDA website (the linked order PDF is dated September 11, 2026). By contrast, a proposed SPF 60+ labeling maximum remains a proposal in the FDA’s current public Q&A. The dates and status matter more than a dramatic headline.

This guide is a source-status ledger for U.S. adults over 40 comparing sunscreen labels. It is not legal advice, a recommendation to discontinue a product, or a claim that our editors tested any sunscreen.

1. Current-status ledger: final orders are not proposals

FDA action	October 30, 2026 status and reader check
Bemotrizinol / OTC000039	Final order issued June 10, 2026. Added to the OTC sunscreen monograph under its stated conditions. This is not approval of every product containing the ingredient.
PABA and trolamine salicylate / OTC000008-1	FDA consumer timeline: September 10, 2026; order PDF header: September 11, 2026. Removes the actives from the monograph, subject to the order’s effective terms. The FDA order states an effective date of September 11, 2027 (or the applicable date under its dispute provision); issuance in September 2026 is not an instant ban on every old package.
Maximum labeled SPF 60+ / OTC000008	2021 proposal, not final. FDA’s current Q&A says the deemed final order has no general SPF maximum. Do not call the proposed cap a current ban on SPF 70 or 100.
Other active-ingredient data questions	Proposed framework and ongoing review. A request for more safety data is not automatically proof that an ingredient is unsafe. Check final orders individually.

2. The June 2026 bemotrizinol decision

The FDA regulatory-actions Q&A lists June 10, 2026 as a final administrative order date for OTC000039, which added bemotrizinol to the sunscreen OTC monograph. A monograph specifies conditions for nonprescription drug marketing; it is not an FDA endorsement of every brand using an ingredient. An online claim of “FDA approved because it contains bemotrizinol” therefore requires a separate check of the product’s actual regulatory status.

If you compare an older article with a newer product, verify the date of the FDA source. A static ingredients list from 2024 or early 2026 may not describe the October 2026 monograph. Neither a retailer’s product-card update nor an influencer’s summary is an adequate substitute for the final order.

3. The September 2026 PABA and trolamine salicylate decision

The FDA consumer sunscreen page and FDA regulatory timeline date the PABA/trolamine salicylate action September 10, 2026, while the cover page of the linked final-order PDF states “Issued September 11, 2026.” These are different dates shown on FDA’s own materials, not evidence of two separate orders. This article records both to avoid masking that discrepancy. The order removes aminobenzoic acid (PABA) and trolamine salicylate from the relevant monograph based on FDA’s safety-risk review. Critically, Section VI of the final order states September 11, 2027 as its effective date, unless the statutory dispute provision applies. The FDA explains that the consequences for marketing products under the monograph apply once the order is in effect. Its consumer Q&A says consumers need take no action because the agency is unaware of U.S.-marketed sunscreens containing either active ingredient. Consumers and retailers should check the actual order and effective-date provisions before asserting that a specific historic label violates the rule on a particular day. The date above comes from Section VI of FDA Final Order OTC000008-1.

For a label audit, record the ingredient name exactly, whether it appears among active ingredients, the full product name, the source date and the order’s effective status. Do not equate incidental mention of an ingredient in an article with its presence as an active on the product label.

4. The SPF 60+ proposal: why a headline can mislead

The FDA Q&A explicitly distinguishes the deemed final order from its 2021 proposal: the deemed final order does not set a general maximum SPF labeling limit; the proposal describes a maximum labeled SPF of 60+, while discussing formulations up to SPF 80. Older news about a proposed SPF 50+ cap should not be mistaken for current law either. Readers assessing an SPF 70 or SPF 100 package should check current FDA guidance and the actual label—not reject it based on a proposal.

A claim seen in an article	Audit outcome
“FDA approved new sunscreen ingredient bemotrizinol in 2026.”	Clarify: added to the OTC monograph under a final order, subject to conditions; not individual product approval
“FDA banned PABA and trolamine salicylate effective immediately.”	Incomplete without the final order’s effective-date and transition language
“FDA now forbids any SPF above 60.”	Incorrect as a statement of the cited currently effective maximum-SPF rule
“All actives for which FDA requested more data are proven unsafe.”	False inference; insufficient data and a safety finding are not identical

5. Reproducible 2026 label verification workflow

Date the statement. Write the day on which you checked the FDA Q&A, not just the publication year of a blog.
Identify the exact action. Record OTC order number and whether it is proposed or final.
Check effective status. A final order’s issuance and its compliance/effective date need not be the same date.
Match the product. Compare active ingredients and labeling with the actual package and current DailyMed record where available.
Write a narrow conclusion. Identify what the evidence proves—and what it cannot prove about an individual product, clinical performance or purchasing preference.

6. An original example of a status-check note

Illustrative example: An October 2026 online article calls SPF 60+ the “new federal ceiling.” A reader opens the dated FDA FAQ, sees the 2021 proposal label, and records “proposal; not a generally effective final SPF maximum in this reference.” That finding corrects a regulatory-status error without asserting anything about the measured quality of an SPF 70 product.

In contrast, for the June 2026 bemotrizinol entry, the same reader records “final monograph order issued” but does not write “FDA approved every sunscreen containing bemotrizinol.” Accurate wording is a meaningful consumer service when rule changes appear in fast-moving product listings.

Frequently asked questions

Can I use a 2021 proposed rule as a 2026 buying rule?

Only as context. First verify which provisions were later finalized, changed or superseded. The FDA’s current Q&A is a starting point, not a substitute for individual order texts.

Does an OTC monograph ingredient automatically make a sunscreen FDA-approved?

No. An OTC monograph sets general requirements for eligible products. FDA marketing authorization concepts and individual product approvals should not be conflated.

Does the September 2026 final order mean I should throw away every older bottle?

This report cannot determine what is appropriate for an individual bottle. Inspect its ingredients, expiration and official order effective dates; consult a qualified clinician or FDA product guidance for health concerns.

Official sources and related checks

Editorial transparency: this is an independent reading and status reconciliation of FDA source documents, not a legal opinion, laboratory test, medical consultation or claim of individual product approval. Revisit current FDA material if reading after October 30, 2026.